Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Adrian_Gottschalk
|
| gptkbp:collaboratesWith |
gptkb:Merck_&_Co.
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
cancer therapeutics
epigenetic drug discovery |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Cigall_Kadoch
Doug Cole |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Foghorn Therapeutics Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
BRG1/BRM inhibitors
CBP/p300 program |
| gptkbp:numberOfEmployees |
100-200 (approximate, as of 2023)
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:FHTX
|
| gptkbp:website |
https://www.foghorntx.com/
|
| gptkbp:bfsParent |
gptkb:FHTX
|
| gptkbp:bfsLayer |
8
|